Topical Skin Bacteria Composition for UV-Induced Cytokine Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for skin conditions caused by UV exposure, such as polymorphic light eruption (PLE), are ineffective in preventing or treating the condition, and there is a lack of understanding of the molecular mechanisms underlying the effects of probiotics on skin immune response.
Innovation Solution
Compositions comprising heterotrophic skin bacteria, particularly Micrococcus luteus, or its bacterial extracts, are formulated for topical application to modulate cytokine expression in skin cells, potentially reducing the secretion of certain cytokines and increasing others to mitigate UV-induced skin damage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies (calamine lotions, topical steroids, hydroxychloroquine) are used to alleviate PLE symptoms, then symptomatic relief may be achieved, but the underlying condition is not effectively treated or prevented and therapeutic efficacy is limited
Solution Approach 1:
The patent applies preliminary action by using probiotic compositions containing Lactobacillus and Bifidobacterium strains before UV exposure to prevent PLE development. The probiotics are administered in advance to modulate the immune response and establish protective mechanisms in the skin, thereby preventing the condition rather than merely treating symptoms after onset.
Solution Approach 2:
The patent uses probiotic bacteria as intermediary organisms that mediate between UV radiation exposure and the immune response. These microorganisms interact with the host immune system to modulate cytokine production and reduce the pathological Th2 response, serving as a biological mediator that bridges the harmful UV exposure and the desired therapeutic immune modulation.
2Reliability
If probiotics are applied topically to modulate immune response, then immune regulation may be achieved, but the molecular mechanisms mediating the effects are poorly characterised and understanding is limited
Solution Approach 1:
The patent employs feedback mechanisms by measuring cytokine profiles (IL-4, IL-5, IL-13 for Th2; IFN-γ, IL-2 for Th1) before and after probiotic treatment to monitor immune response modulation. This feedback approach allows characterization of the molecular mechanisms by which probiotics regulate the immune system, providing quantitative data on cytokine changes that reveal the underlying biological processes.
Solution Approach 2:
The patent replaces the mechanical/symptomatic approach of current therapies with a biological mechanism-based approach using probiotics. Instead of relying on topical steroids that merely suppress inflammation, the invention uses living microorganisms that actively modulate immune pathways through molecular interactions, substituting a mechanistic biological system for a symptomatic mechanical treatment.
3Adaptability or versatility
If UV radiation exposure occurs, then normal Th2 cell activation may proceed, but Th1 cell function is suppressed resulting in a shift to a Th2-like phenotype that causes disease
Solution Approach 1:
The patent applies the counterweight principle by using probiotic bacteria to counterbalance the UV-induced suppression of Th1 responses. The probiotics stimulate Th1 cytokine production (IFN-γ, IL-2) to counterweight the excessive Th2 activity, restoring the normal Th1-Th2 balance and preventing the pathological Th2-like phenotype shift that causes PLE.
Solution Approach 2:
The patent changes the parameters of the immune response by modulating cytokine production levels. The probiotic composition alters the quantitative balance between Th1 and Th2 cytokines, shifting the immune response parameters from a suppressed Th1/excessive Th2 state to a balanced state, thereby preventing disease development while maintaining appropriate immune versatility.
Data Source
AI summary
The present invention relates to a composition comprising a heterotrophic skin bacterium and/or heterotrophic skin bacterial extract for use in the modulation of cytokine expression in a skin cell. The composition is particularly suited for use in the prevention and/or treatment of skin damage caused by UV light and use in treating skin conditions such as polymorphous light eruption (PLE).